temozolomide has been researched along with Nervous System Disorders in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " CB related adverse events occurring in more than one patient were fatigue, gait disturbance, nystagmus, and confusion." | 6.73 | Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. ( Asher, AL; Chang, SM; Croteau, D; Grahn, AY; Husain, SR; Kunwar, S; Lang, FF; Parker, K; Puri, RK; Sampson, JH; Shaffrey, M; Sherman, JW; Vogelbaum, MA, 2007) |
| " We have compiled the treatment experience of seven neurosurgical centers using implantation of carmustine wafers at primary surgery followed by 6 weeks of radiation therapy (59-60 Gy) and 75 mg/m(2)/day TMZ in patients with newly diagnosed glioblastoma followed by TMZ monochemotherapy." | 3.76 | First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. ( Bock, HC; Buchalla, R; Giese, A; Kantelhardt, SR; Ketter, R; Koll, S; Lohmann, F; Puchner, MJ; Rainov, N; Rohde, V; Schütze, M, 2010) |
| " CB related adverse events occurring in more than one patient were fatigue, gait disturbance, nystagmus, and confusion." | 2.73 | Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. ( Asher, AL; Chang, SM; Croteau, D; Grahn, AY; Husain, SR; Kunwar, S; Lang, FF; Parker, K; Puri, RK; Sampson, JH; Shaffrey, M; Sherman, JW; Vogelbaum, MA, 2007) |
| "Angiocentric glioma is a recently recognized benign brain tumor with unknown histogenesis." | 1.39 | Malignant glioma with angiocentric features. ( Lu, JQ; Mehta, V; Patel, S; Pugh, J; Wilson, BA, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Łata, S | 1 |
| Molczyk, A | 1 |
| Bock, HC | 1 |
| Puchner, MJ | 1 |
| Lohmann, F | 1 |
| Schütze, M | 1 |
| Koll, S | 1 |
| Ketter, R | 1 |
| Buchalla, R | 1 |
| Rainov, N | 1 |
| Kantelhardt, SR | 1 |
| Rohde, V | 1 |
| Giese, A | 1 |
| Lu, JQ | 1 |
| Patel, S | 1 |
| Wilson, BA | 1 |
| Pugh, J | 1 |
| Mehta, V | 1 |
| Vairano, M | 1 |
| Graziani, G | 1 |
| Tentori, L | 1 |
| Tringali, G | 1 |
| Navarra, P | 1 |
| Dello Russo, C | 1 |
| Vogelbaum, MA | 1 |
| Sampson, JH | 1 |
| Kunwar, S | 1 |
| Chang, SM | 1 |
| Shaffrey, M | 1 |
| Asher, AL | 1 |
| Lang, FF | 1 |
| Croteau, D | 1 |
| Parker, K | 1 |
| Grahn, AY | 1 |
| Sherman, JW | 1 |
| Husain, SR | 1 |
| Puri, RK | 1 |
1 trial available for temozolomide and Nervous System Disorders
| Article | Year |
|---|---|
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
4 other studies available for temozolomide and Nervous System Disorders
| Article | Year |
|---|---|
[Side effects of temozolomide treatment in patient with glioblastoma multiforme--case study].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2010 |
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2010 |
Malignant glioma with angiocentric features.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2013 |
Primary cultures of microglial cells for testing toxicity of anticancer drugs.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Culture Te | 2004 |